Gene

RAD50

RAD50 double strand break repair protein

Explore in graph →CI-GENE-00022859HGNC:9816 ENSG00000113522 NCBI 10111 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RAD50 L1237F1
Checkpoint Kinase Inhibitor AZD7762 + IrinotecanCombination	Ureter Small Cell Neuroendocrine CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	4	accepted	EID5829 A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinot… (full text at CIViC) PMID 24934408 · Al-Ahmadie et al., 2014 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (91)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved91 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Comparison of Cutaneous Sarcomas, CSCC and Deeper Sarcomas (DFCI, 2026) sarcoma_dfci_genie_2026	unmapped	Ssm	8	48	16.7%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
· Cancer Discov · 2014 · PMID 24934408 · validated civic_curation pubmed